The association between urinary bisphenol A levels and nonalcoholic fatty liver disease in Korean adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017.
Bisphenol A
Hepatic steatosis index
Korean adults
Korean national environmental health survey
Nonalcoholic fatty liver disease
Journal
Environmental health and preventive medicine
ISSN: 1347-4715
Titre abrégé: Environ Health Prev Med
Pays: Japan
ID NLM: 9609642
Informations de publication
Date de publication:
14 Sep 2021
14 Sep 2021
Historique:
received:
22
06
2021
accepted:
29
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is becoming a global health problem. Bisphenol A (BPA), one of most widely used environmental chemicals, is suspected to be a contributor to the development NAFLD. This study was performed to examine the relationship between human BPA levels and risk of NAFLD. The data (n = 3476 adults: 1474 men and 2002 women) used in this study were obtained from the Korean National Environmental Health Survey III (2015-2017). BPA levels were measured in urine samples. NAFLD was defined using hepatic steatosis index after exclusion of other causes of hepatic diseases. There was a significant linear relationship between the elevated urinary BPA concentrations and risk of NAFLD. In a univariate analysis, odds ratio (OR) of the highest quartile of urinary BPA level was 1.47 [95% confidence interval (CI) 1.11-1.94] compared to the lowest quartile. After adjusted with covariates, the ORs for NAFLD in the third and fourth quartiles were 1.31 [95% CI 1.03-1.67] and 1.32 [95% CI 1.03-1.70], respectively. Urinary BPA levels are positively associated with the risk of NAFLD in adults. Further experimental studies are needed to understand the molecular mechanisms of BPA on NAFLD prevalence.
Sections du résumé
BACKGROUND
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is becoming a global health problem. Bisphenol A (BPA), one of most widely used environmental chemicals, is suspected to be a contributor to the development NAFLD. This study was performed to examine the relationship between human BPA levels and risk of NAFLD.
METHODS
METHODS
The data (n = 3476 adults: 1474 men and 2002 women) used in this study were obtained from the Korean National Environmental Health Survey III (2015-2017). BPA levels were measured in urine samples. NAFLD was defined using hepatic steatosis index after exclusion of other causes of hepatic diseases.
RESULTS
RESULTS
There was a significant linear relationship between the elevated urinary BPA concentrations and risk of NAFLD. In a univariate analysis, odds ratio (OR) of the highest quartile of urinary BPA level was 1.47 [95% confidence interval (CI) 1.11-1.94] compared to the lowest quartile. After adjusted with covariates, the ORs for NAFLD in the third and fourth quartiles were 1.31 [95% CI 1.03-1.67] and 1.32 [95% CI 1.03-1.70], respectively.
CONCLUSIONS
CONCLUSIONS
Urinary BPA levels are positively associated with the risk of NAFLD in adults. Further experimental studies are needed to understand the molecular mechanisms of BPA on NAFLD prevalence.
Identifiants
pubmed: 34521354
doi: 10.1186/s12199-021-01010-7
pii: 10.1186/s12199-021-01010-7
pmc: PMC8442282
doi:
Substances chimiques
Benzhydryl Compounds
0
Phenols
0
bisphenol A
MLT3645I99
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Subventions
Organisme : national research foundation of korea
ID : NRF-2021R1I1A3046386
Informations de copyright
© 2021. The Author(s).
Références
Hepatology. 2012 Feb;55(2):395-407
pubmed: 21932408
Diabetes Metab Syndr Obes. 2018 Sep 25;11:533-542
pubmed: 30288073
Environ Int. 2015 Oct;83:107-15
pubmed: 26115537
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Life Sci. 2020 Sep 1;256:118012
pubmed: 32593710
Medicine (Baltimore). 2017 Apr;96(17):e6770
pubmed: 28445310
Toxicol In Vitro. 2012 Aug;26(5):709-17
pubmed: 22515966
Environ Int. 2021 Jan;146:106227
pubmed: 33152652
World J Hepatol. 2016 Dec 28;8(36):1610-1616
pubmed: 28083083
Toxicology. 2003 Jun 30;188(2-3):117-24
pubmed: 12767684
N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
J Hepatol. 2017 Oct;67(4):862-873
pubmed: 28642059
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Ann Saudi Med. 2010 Jan-Feb;30(1):25-32
pubmed: 20103955
Environ Res. 2019 Sep;176:108575
pubmed: 31299621
Ann Occup Environ Med. 2019 Sep 09;31:e23
pubmed: 31620300
Int J Environ Res Public Health. 2020 May 12;17(10):
pubmed: 32408667
Environ Toxicol Pharmacol. 2015 Jul;40(1):241-58
pubmed: 26164742
Aliment Pharmacol Ther. 2018 Mar;47(6):826-837
pubmed: 29322544
Dose Response. 2015 Jul 29;13(3):1559325815598308
pubmed: 26674671
Liver Int. 2019 Jul;39(7):1335-1342
pubmed: 30924602
Transl Gastroenterol Hepatol. 2020 Apr 05;5:16
pubmed: 32258520
Drug Metab Dispos. 2005 Nov;33(11):1748-57
pubmed: 16103135
Environ Res. 2011 Nov;111(8):1280-5
pubmed: 21925656
NTP CERHR MON. 2008 Sep;(22):v, vii-ix, 1-64 passim
pubmed: 19407859
Cureus. 2018 Nov 23;10(11):e3626
pubmed: 30697502
J Endocr Soc. 2018 Sep 12;2(10):1173-1187
pubmed: 30302422
Environ Health Perspect. 2005 Apr;113(4):391-5
pubmed: 15811827
Nat Rev Endocrinol. 2017 Aug;13(8):445-457
pubmed: 28524171
Dig Liver Dis. 2010 Jul;42(7):503-8
pubmed: 19766548
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276
pubmed: 29307986
J Clin Endocrinol Metab. 2012 Feb;97(2):E223-7
pubmed: 22090277
Clin Exp Hepatol. 2020 Dec;6(4):289-294
pubmed: 33511275
Children (Basel). 2018 May 25;5(6):
pubmed: 29799476
Neuropathology. 2012 Aug;32(4):447-57
pubmed: 22239237
Clin Endocrinol (Oxf). 2017 Apr;86(4):506-512
pubmed: 27801986